Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Better Therapeutics Inc (BTTX)

Better Therapeutics Inc (BTTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 449
  • Shares Outstanding, K 49,862
  • Annual Sales, $ 0 K
  • Annual Income, $ -39,760 K
  • 60-Month Beta 2.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BTTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.15
  • Most Recent Earnings $-0.15 on 11/09/23
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 360.47%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +256,253.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0050 +100.00%
on 04/05/24
0.0175 -42.86%
on 03/27/24
-0.0037 (-27.01%)
since 03/26/24
3-Month
0.0050 +100.00%
on 04/05/24
0.2400 -95.83%
on 02/20/24
-0.1765 (-94.64%)
since 01/26/24
52-Week
0.0050 +100.00%
on 04/05/24
1.3500 -99.26%
on 07/11/23
-1.2000 (-99.17%)
since 04/26/23

Most Recent Stories

More News
Stocks Move Higher Before the Open as Investors Weigh Fed Comments, U.S. CPI Looms

September S&P 500 futures (ESU23) are up +0.10%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.13% this morning after three major U.S. benchmark indices ended the regular session higher as...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
IEP : 17.25 (-0.12%)
INTC : 31.88 (-9.20%)
QCOM : 165.66 (+1.45%)
CAVA : 69.16 (+10.50%)
FMC : 58.46 (+1.14%)
GOOGL : 171.95 (+10.22%)
AMZN : 179.62 (+3.43%)
DTG.D.DX : 42.910 (+2.61%)
BTTX : 0.0100 (+11.11%)
WDFC : 225.52 (+0.14%)
Dr. Reddy's (RDY) Q4 Earnings and Revenues Beat Estimates

Dr. Reddy's (RDY) reports better-than-expected fourth-quarter results where both earnings and revenues beat estimates.

RDY : 74.55 (+0.72%)
IMGN : 31.23 (unch)
AZYO : 1.4900 (+2.05%)
BTTX : 0.0100 (+11.11%)
Catalyst's (CPRX) Q1 Earnings Lag, Sales Boost Revenues

Catalyst (CPRX) reports mixed results for the first quarter, wherein earnings miss and revenues beat estimates. Fycompa sales boost revenues. The company maintains revenue guidance. The stock surges 3%....

IMGN : 31.23 (unch)
CPRX : 14.89 (+1.43%)
AZYO : 1.4900 (+2.05%)
BTTX : 0.0100 (+11.11%)
Better Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the...

BTTX : 0.0100 (+11.11%)
Indaptus (INDP) Surges on Upbeat Pre-Clinical Decoy Data

Indaptus (INDP) announces positive pre-clinical efficacy data from a poster presentation made at a scientific conference from its proprietary Decoy platform pre-clinical study. Stock is up 22%.

RCEL : 8.52 (+2.65%)
INDP : 2.11 (-3.21%)
BTTX : 0.0100 (+11.11%)
EQRX : 2.34 (-2.09%)
Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent

Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.

AUPH : 4.91 (+0.82%)
RCEL : 8.52 (+2.65%)
BTTX : 0.0100 (+11.11%)
EQRX : 2.34 (-2.09%)
Better Therapeutics, Inc. (BTTX) Moves to Buy: Rationale Behind the Upgrade

Better Therapeutics, Inc. (BTTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BTTX : 0.0100 (+11.11%)
Better Therapeutics Announces $6.5MM Private Placement

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address...

BTTX : 0.0100 (+11.11%)
Better Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address...

BTTX : 0.0100 (+11.11%)
Better Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 30, 2023

Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the...

BTTX : 0.0100 (+11.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Better Therapeutics Inc. is a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases. Better Therapeutics Inc., formerly known as Mountain Crest Acquisition Corp II, is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 0.0147
2nd Resistance Point 0.0133
1st Resistance Point 0.0117
Last Price 0.0100
1st Support Level 0.0087
2nd Support Level 0.0073
3rd Support Level 0.0057

See More

52-Week High 1.3500
Fibonacci 61.8% 0.8362
Fibonacci 50% 0.6775
Fibonacci 38.2% 0.5188
Last Price 0.0100
52-Week Low 0.0050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar